TSC22D1

Across TCGA pan-cancer cohorts, TSC22D1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of TSC22D1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TSC22D1 RNA is repressed in tumor relative to normal tissue. In most cancer types TSC22D1 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

BLCA, KICH, and THCA are the cancer types where TSC22D1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TSC22D1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	−1.638	<.001	12	view →
KICH	Male	III,IV	−2.962	<.001	11	view →
THCA	All	II,III,IV	+1.473	<.001	9	view →
LUAD	All	III,IV	−1.045	<.001	9	view →
BRCA	Female	All	−0.761	<.001	8	view →
LUSC	All	II,III,IV	−1.258	<.001	7	view →
LIHC	Male	II,III,IV	+1.481	<.001	5	view →
UCEC	All	All	−0.864	<.001	2	view →
COAD	Female	II,III,IV	−0.409	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

TSC22D1–BLCA

Open the BLCA breakdown →